S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:PRTK

Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.19
$2.24
50-Day Range
$2.17
$2.23
52-Week Range
$1.29
$3.65
Volume
4.76 million shs
Average Volume
724,253 shs
Market Capitalization
$127.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.58

Paratek Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
60.3% Upside
$3.58 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.98
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.54 out of 5 stars

Medical Sector

879th out of 939 stocks

Biotechnology Industry

29th out of 36 stocks

PRTK stock logo

About Paratek Pharmaceuticals Stock (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

PRTK Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
PRTK Paratek Pharmaceuticals, Inc.
See More Headlines
Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CUSIP
89354M10
Employees
268
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$3.58
High Stock Price Target
$5.00
Low Stock Price Target
$2.15
Potential Upside/Downside
+60.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-63,570,000.00
Pretax Margin
-35.35%

Debt

Sales & Book Value

Annual Sales
$160.27 million
Book Value
($3.08) per share

Miscellaneous

Free Float
52,736,000
Market Cap
$127.82 million
Optionable
Optionable
Beta
1.70

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

PRTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Paratek Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares.
View PRTK analyst ratings
or view top-rated stocks.

What is Paratek Pharmaceuticals' stock price target for 2024?

2 analysts have issued 1-year price targets for Paratek Pharmaceuticals' shares. Their PRTK share price targets range from $2.15 to $5.00. On average, they expect the company's share price to reach $3.58 in the next year. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for PRTK
or view top-rated stocks among Wall Street analysts.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analysts' expectations of $22.98 million. During the same quarter in the previous year, the firm posted ($0.46) EPS.

What ETF holds Paratek Pharmaceuticals' stock?

AltShares Event-Driven ET holds 17,764 shares of PRTK stock, representing 1.36% of its portfolio.

What other stocks do shareholders of Paratek Pharmaceuticals own?
This page (NASDAQ:PRTK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners